MedTrace Logo

A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.

NCT00721422 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2010-02-17

No results posted yet for this study

Summary

1. To investigate the effect of kidney function on the elimination of a single dose of PD 0332334 from the body.
2. To investigate the safety and tolerability of a single dose of PD 0332334 in patients with impaired kidney function.

Conditions

  • Renal Insufficiency
  • Pharmacokinetics

Interventions

DRUG

PD 0332334

50 mg (two 25 mg capsules), single, oral dose

DRUG

PD 0332334

50 mg (two 25 mg capsules), single, oral dose

DRUG

PD 0332334

50 mg (two 25 mg capsules), single, oral dose

DRUG

PD 0332334

50 mg (two 25 mg capsules), single, oral dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00721422 on ClinicalTrials.gov